FDA Approves Merck’s Keytruda (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple‑Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)
KENILWORTH, N.J.–(BUSINESS WIRE) November 13, 2020 — Merck (NYSE: MRK), known as MSD outside the United States and Canada, today
Read more
